Navigation Links
For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over Carvedilol in the Treatment of Coronary Heart Disease (Stable Angina)
Date:4/20/2009

Percutaneous Coronary Intervention Will Retain Decision Resources' Clinical Gold Standard for Stable Angina, According to a New Report from Decision Resources

WALTHAM, Mass., April 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists identify a therapy's effect on mortality as the attribute that most influences their prescribing decisions in coronary heart disease (stable angina). Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage in this attribute over carvedilol (GlaxoSmithKline's Coreg, generics), the sales-leading agent in the market.

The new report entitled Coronary Heart Disease (Stable Angina): To Gain Share, Emerging Therapies Must Not Only Control Symptoms but Also Reduce Mortality also finds that a therapy that reduces plaque volume more than Pfizer's Lipitor/Sortis/Tahor at 18 months would earn a 28 percent patient share in stable angina in the United States and a 37 percent patient share in Europe, according to surveyed U.S. and European cardiologists.

In 2008, Decision Resources' proprietary clinical gold standard for stable angina was percutaneous coronary intervention (PCI). Based on available data and expert opinion, PCI will retain gold-standard status for stable angina in 2012 as surveyed physicians believe it to be the most efficacious therapy for treating the symptoms of stable angina.

"Interestingly, surveyed physicians also indicate that Cardium Therapeutics' gene therapy Generx has great potential in treating stable angina," said Decision Resources Analyst Kate Sullivan, B.S. "However, experts we interviewed believe gene therapy is still at least 10 years away from becoming a viable therapeutic approach for the indication, which leaves PCI, over the next decade, as the most e
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers
2. New Mexican health-care program successful at reducing crippling health care costs
3. Mexican health care program successful at reducing crippling health care costs
4. Angiogenesis inhibitor improves brain tumor survival by reducing edema
5. ADD-care -- A Natural, Homeopathic Alternative Reducing Symptoms Related to Attention Deficit Disorder
6. Employment Technologies Announces Pre-release of EASyView Virtual Interview System, Reducing Employer Time and Costs
7. Reducing suicidal behaviors among adolescents
8. Experts in Government, Public Health, Public Policy and Science Outline Blueprint for Reducing Death and Disease From Tobacco in the United States
9. Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma
10. The New Crystalens HD Gives Many Baby Boomers and Seniors an Opportunity to See Clearly at All Distances while Reducing or Eliminating the Need for Glasses
11. Effectiveness of Progesterone in Reducing Preterm Births May Be Altered by Genetic Predisposition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 It is almost ... sprint or walk for healthier and happier kids. The ... participate in the 4th Annual Miami Children’s Hospital 5K Run/Walk. ... http://www.hyundaihopeonwheels.org , The 5K will take place ... will be outside of Coral Gables City Hall located at ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Clinical trial ... data on the Edema clinical trial scenario. This report ... trials on Edema. It includes an overview of the ... site of trial conduction across the globe. The databook ... their phase, trial status, prominence of the sponsors and ...
(Date:9/18/2014)... PA (PRWEB) September 18, 2014 ... announces the launch of Good Neighbor Pharmacy University, ... access information that will educate and empower pharmacy ... “As the healthcare industry continues to evolve, Good ... as we deliver resources and tools to help ...
(Date:9/18/2014)... September 18, 2014 CD-adapco, the largest ... software, today announced its new partnership with Ben Ainslie ... CD-adapco simulation tool, STAR-CCM+® in the design of its ... participation in the 35th America’s Cup taking place in ... the America’s Cup is sustainability, the set of restrictive ...
(Date:9/18/2014)... more vegetables and drink less sugar, according to a ... it,s still not enough, the study goes on to ... comes to eating healthier at school , The research ... status, may inform a child,s diet. , The study ... education were 85 per cent more likely to eat ...
Breaking Medicine News(10 mins):Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Good Neighbor Pharmacy University Keeps Pharmacists Ahead of the Curve 2Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2Health News:Kids eat better if their parents went to college 2
... a study published in the recent issue of Annals ... exercise //as preconditions to prevent and control diabetes type ... cost effective to control diabetes through rigorous exercise and ... diabetes reduces the body’s ability to store calories, resulting ...
... at the annual meeting of the American Academy of Orthopedic ... back pain may be the result of several problems other ... restrict the effect of a surgery. The study that had ... National Spine Network, US, said that patients who had other ...
... 100 patients at an ear , nose and throat clinic ... snoring // shouldn't expect to receive a diagnosis of obstructive ... examination alone instead an overnight sleep testing needs to be ... ,For the study, physicians evaluated the patients with a ...
... now that after delivery depressions, that had plagued new mothers all ... the delivery. As a result of this belief, many pregnant women ... new study that comes in the recent issue of British Medical ... to Deirdre Murphy of Dundee University, who had led the team ...
... twins and their mothers to see if there was a ... // of life and children's antisocial behavior by age 7 ... have increased problems with conduct and more antisocial behavior . ... the twins' birth and the likeliness of antisocial behavior in ...
... to treat agitation in patients with Alzheimer's or dementia, ... findings of a recent study .// ,For ... Twenty-six of the patients received quetiapine (an antipsychotic also ... also known as Exelon), and 29 received a placebo. ...
Cached Medicine News:
(Date:9/18/2014)... , Sept. 18, 2014 MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today that it has entered into a ... MiMedx will provide its dehydrated human amnion/chorion membrane ... non- exclusively on a private label basis. ...
(Date:9/18/2014)... 18, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has removed the ... PEGPH20 in SWOG,s ongoing Phase 1b/2 clinical trial ... investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in ... with metastatic pancreatic adenocarcinoma.  The study will resume ...
(Date:9/18/2014)... -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company ... announced today that it has appointed Mr. Christopher ... of Clinical Development. During his extensive career ... successful global clinical operations teams, in the US and ... development of numerous therapeutics and diagnostics across a broad ...
Breaking Medicine Technology:MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... (ASX: PGL; Nasdaq: PGLA) today announced additional,data from the ... this,year. This data was presented at the 58th Annual ... Diseases in Boston, USA(1). As the Phase 2 ... data analysis described in this presentation was performed to,evaluate ...
... overall rate of sustained virologic response in ... long-acting interferons in ... Albuferon non-responder study presented at the, Annual Meeting of the American Association for the Study ... ...
Cached Medicine Technology:Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 2Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: